Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 2/20 | 0.48 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | PRKACA | P17612 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4239980 | 0.81 | DPP7 (0.59) | SCN8ATAAR1DPP7SIGMAR1ALKBH5 | |
| SCHEMBL1846887 | 0.80 | HDAC3 (0.49) | ROCK1ROCK2PRKACAGSK3BCLK4 | |
| SCHEMBL2475485 | 0.78 | TAAR1 (0.62) | ROCK1TAAR1ROCK2RPS6KB1BCHE | |
| SCHEMBL4245195 | 0.76 | DPP7 (0.55) | SCN8ATAAR1DPP7BCHEKDM4E | |
| SCHEMBL3155807 | 0.76 | CHRM2 (0.52) | SCN8AHDAC3HDAC1HDAC2BCHE | |
| SCHEMBL5227682 | 0.75 | DPP7 (0.57) | ROCK1SCN8ATAAR1DPP7ALKBH5 | |
| SCHEMBL11700971 | 0.74 | MAOB (0.60) | TAAR1MRGPRX4 | |
| SCHEMBL2474802 | 0.73 | TAAR1 (0.57) | TAAR1 | |
| SCHEMBL1795069 | 0.73 | CYP1A2 (0.66) | TAAR1 | |
| SCHEMBL7243973 | 0.72 | MAOB (0.57) | ROCK1SCN8ATAAR1DPP7ALKBH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137653-A1 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | INFLAYZME PHARMACEUTICALS LTD. (CA) | 2009-05-28 | — | — | US | disclosed |
| EP-1871357-A2 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | Inflazyme Pharmaceuticals, Ltd. (CA) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006108149-A2 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137653-A1 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | CYP2A6, CYP2B6, CYP2D6 | ROCK1 4439/4885SCN8A 1026/4885TAAR1 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.